![Inside Honeywell’s plan for a new F-35 cooling system [Video]](https://breakingdefense.com/wp-content/uploads/sites/3/2024/07/8509355-1-scaled-e1721820217290.jpg?#)
BMS expands radiopharma pipeline via RayzeBio's $1.3B prostate cancer drug deal
Bristol Myers Squibb, via its RayzeBio unit, is handing out $350 million in upfront cash for a phase 1-stage radiopharmaceutical therapy and diagnostic for prostate cancer.
Bristol Myers Squibb, via its RayzeBio unit, is handing out $350 million in upfront cash for a phase 1-stage radiopharmaceutical therapy and diagnostic for prostate cancer.
